Group 1 - The China Securities Innovation Drug Industry Index rose by 0.1% at midday, while the CSI 300 Healthcare Index fell by 0.02%, the CSI Biotech Theme Index decreased by 0.1%, the Hang Seng Hong Kong Stock Connect Healthcare Comprehensive Index dropped by 0.7%, and the Hang Seng Hong Kong Stock Connect Innovation Drug Index declined by 0.9% [1] Group 2 - The CSI Biotech Theme Index focuses on A-share biotech leaders and consists of no more than 50 companies involved in areas such as gene diagnostics, biopharmaceuticals, and blood products [4] - The CSI 300 Healthcare Index targets A-share healthcare industry leaders and includes companies from the CSI 300 Index that are involved in chemical pharmaceuticals, medical services, and medical devices [4] - The indices have been published since 2015 for the Biotech Theme Index and since 2007 for the CSI 300 Healthcare Index, with respective rolling price-earnings ratios of 33.9 times and 65.7% valuation percentile [4]

Group 1 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks primarily involved in innovative drug research and development [3] - As of the midday close, the index has increased by 0.5% with a rolling price-to-earnings ratio of 53.0 times, reflecting an 80.5% increase in valuation since its launch [4] Group 2 - The biotechnology ETF tracks the China Securities Biotechnology Theme Index, focusing on leading biotechnology companies in the A-share market, including those involved in gene diagnosis, biopharmaceuticals, and blood products [5] - As of the midday close, the biotechnology index has remained unchanged at 0.0% with a rolling price-to-earnings ratio of 55.6 times, indicating a 67.4% increase in valuation since its inception [5] Group 3 - The pharmaceutical ETF tracks the CSI 300 Healthcare Index, concentrating on leading companies in the A-share healthcare sector, covering segments such as chemical pharmaceuticals, medical services, and medical devices [6] - As of the midday close, the pharmaceutical index has increased by 0.2% with a rolling price-to-earnings ratio of 31.0 times, showing a 47.9% increase in valuation since its launch [7]

Market Performance - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.5% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.3% [1] - The China Securities Biotechnology Theme Index and the China Securities Innovative Drug Industry Index both saw an increase of 0.7% and 0.5% respectively [1] - The CSI 300 Pharmaceutical and Health Index grew by 0.6% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net subscription of 18 million units, reaching a record high of 1.26 billion yuan [1] Index Details - The Biotechnology ETF tracks the China Securities Biotechnology Theme Index, which focuses on leading A-share biotechnology companies involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [4] - The rolling price-to-earnings (P/E) ratio for the Biotechnology Theme Index is 55.3 times, with a valuation percentile of 0.7% [5] - The Pharmaceutical ETF tracks the CSI 300 Pharmaceutical and Health Index, covering major companies in the pharmaceutical and health sector, including chemical pharmaceuticals, medical services, and medical devices [6][7] - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 30.7 times, with a valuation percentile of 45.7% [7] ETF Characteristics - The Hang Seng Innovative Drug ETF is the only ETF tracking the innovative drug index, with a low management fee of 0.15% per year and a custody fee of 0.05% per year [9]